C-myc as a predictive marker for chemotherapy in metastatic breast cancer

Clinical and Experimental Medicine

Volumn 12, Issue 4, 2012, Pages 217-223

  Todorović Raković, Nataša ^a   Nešković Konstantinović, Zora ^a   Nikolić Vukosavljevic, Dragica ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

Amplification; C myc; Chemotherapy; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; ONCOGENE C MYC; PREDICTIVE VALUE; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG THERAPY; FLUOROURACIL; HUMANS; METHOTREXATE; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS C-MYC; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84870440054     PISSN: 15918890     EISSN: 15919528     Source Type: Journal    
DOI: 10.1007/s10238-011-0169-y     Document Type: Article

References (48)

1. Dang CV (1999) C-myc target genes involved in cell growth, apoptosis and metabolism. Mol Cell Biol 19:1-11 (Pubitemid 29018404)
2. Cappellen D, Schlange T, Bauer M, Maurer M, Hynes NE (2007) Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8:70-76 (Pubitemid 46043803)
3. Lutz W, Leon J, Eilers M (2002) Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602:61-71 (Pubitemid 34311900)
4. Liao DJ, Dickson RB (2000) C-myc in breast cancer. Endocr Relat Cancer 7:143-164
5. Berns EM, Foekens JA, van Putten WL, van Staveren IL, Portengen H, de Koning WC, Klijn JG (1992) Prognostic factors in human primary breast cancer: comparison of c-myc and HER2/ neu amplification. J Steroid Biochem Mol Biol 43:13-19
6. Berns EM, Kiijn JG, van Starveren IL, Portengen H, de Koning WC, Foekens JA (1992) Prevalence of amplification of the oncogene c-myc, HER2/neu, and int-2 in one thousand human breast tumors: correlation with steroid receptor status. Eur J Cancer 28:697-700
7. Scorilas A, Trangas T, Yotis J, Pateras C, Talieri M (1999) Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin D and clinicopathological characteristics using univariate and multivariate analysis. Br J Cancer 81:1385-1391
8. Rummukainen JK, Salminen T, Lundin J, Kyto?la? S, Joensuu H, Isola JJ (2001) Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 14:1030-1035 (Pubitemid 32976792)
9. Hermeking H (2003) The Myc oncogene as a cancer drug target. Curr Cancer Drug Targets 3:163-175 (Pubitemid 36565759)
10. Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D (2007) Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Exp Mol Pathol 82:262-268 (Pubitemid 46691311)
11. Todorović-Raković N, Nesković-Konstantinović Z, Nikolić-Vukosavljević D (2009) Metastatic breast cancer survival according to HER2 and Topo2a gene status. Dis Markers 26:171-180
12. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R (1986) Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. PNAS 83:4834-4838 (Pubitemid 16075494)
13. Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P (1988) In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665-671
14. Harada Y, Katagiri T, Ito I, Sakamoto G, Kasumi F, Nakamura Y, Emi M (1994) Genetic studies of 457 breast cancers. Clinocopathological parameters compared with genetic alterations. Cancer 74:2281-2286 (Pubitemid 24322283)
15. Contegiacomo A, Pizzi C, De Marchis L, Alimandi M, Delrio P, Di Palma E et al (1995) High cell kinetics is associated with amplification of the int-1, bcl1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancer. Int J Cancer 61:1-6
16. Ito I, Yoshimoto M, Iwase T, Watanabe H, Katagiri T, Harada Y et al (1995) Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer 71:438-441
17. Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C (1989) Proto-oncogene amplification and human breast cancer phenotype. Oncogene 4:1389-1395 (Pubitemid 19273395)
18. Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y et al (1991) Immunohistochemical study of oncogene product ras 21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 11:1485-1494
19. Courjal F, Theillet C (1997) Comparative genomic hybridization analysis of breast tumors with predetermined profiles of DNA amplification. Cancer Res 57:4368-4377 (Pubitemid 27413448)
20. Cuny M, Kramer A, Courjal F, Johannsdottir V, Iacopetta B, Fontaine H et al (2000) Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60:1077-1083 (Pubitemid 30129548)
21. Persons DL, Borelli KA, Hsu PH (1997) Quantitation of HER-2/ neu and c-myc gene amplification in breast carcinoma using fluorescent in situ hybridization. Mod Pathol 10:720-727 (Pubitemid 27321765)
22. Kreipe H, Feist H, Fischer L, Feigner J, Heidorn K, Mettler L, Parwarech R (1993) Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-1961 (Pubitemid 23127131)
23. Deming SL, Nass SJ, Dickson RB, Trock JB (2000) C-myc amplification in breast cancer: a meta analysis of its occurrence and prognostic relevance. Br J Cancer 83(12):1688-1695 (Pubitemid 32001715)
24. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH (2011) Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol 25:1527-1538
25. Wang Y, Liu S, Zhang G, Zhou C, Zhu H, Zhou X et al (2005) Knockdown of c-myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res 7:R220-R228
26. Dubik D, Shiu RP (1988) Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705-12708 (Pubitemid 19000455)
27. Bernstein PL, Herrick DJ, Prokipcak RD, Ross J (1992) Control of c-myc mRNA half-life in vitro by a protein capable of binding to a coding region stability determinant. Genes Dev 6:642-654
28. Wong MSJ, Murphy LC (1991) Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 39:39-44
29. Musgrove EA, Lee CS, Sutherland RL (1991) Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11(10):5032-5043 (Pubitemid 21895264)
30. Robarius-Mandag EC, Bosch CA, Kristel PM, Hart AAM, Farieyte IF, Nederlof PM et al (2003) Association of c/myc amplification with progression from the in situ to the invasive stage in c-myc amplified breast carcinomas. J Pathol 201:75-82 (Pubitemid 37121205)
31. Rodriguez-Pinilla SM, Jones RL, Lambros MBK, Arriola E, Savage K, James M et al (2007) MYC amplification in breast cancer: a chromogenic in situ hybridization study. J Clin Pathol 60:1017-1023 (Pubitemid 47441935)
32. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, Sinn HP (2006) C-myc amplifications in primary breast carcinomas and their local recurrences. J Clin Pathol 59:424-428
33. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN et al (2009) MYC regulation of a ''poor-prognosis'' metastatic cancer cell state. PNAS 107:3698-3703
34. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H (1992) C-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687-691
35. Roux-Dosseto M, Romain S, Dissault N, Desiders C, Piana L, Bonnier P et al (1992) C-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer 2:1600-1604
36. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G (1988) Overexpression of either c-myc or c-erbB2 protooncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3:21-31 (Pubitemid 19036476)
37. Mimori K, Mori M, Shiraishi T, Tanaka S, Haraguchi M, Ueo H et al (1998) Expression of ornithine decarboxylase mRNA and c-myc mRNA in breast tumors. Int J Oncol 12:597-601 (Pubitemid 28097288)
38. Mizukami Y, Nonomura A, Noguchi M, Taniya T, Koyasaki N, Saito Y et al (1991) Immunohistochemical study of oncogene product ras 21, c-myc and growth factor EGF in breast carcinomas. Anticancer Res 11:1485-1494
39. Gutman M, Ravia Y, Assaf D, Yamamoto T, Rozin R, Shifon Y (1989) Amplification of c-myc and c-erbB2 proto-oncogenes in human solid tumors: frequency and clinical significance. Int J Cancer 44:802-805 (Pubitemid 20007975)
40. Bieche I, Laurendau I, Tozlu S, Olivi M, Vidaud D, Lidereau R et al (1999) Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 59:2759-2765 (Pubitemid 29283103)
41. Pietilainen T, Lipponen P, Aaltuman S, Eskelinen M, Kosma VM, Syrjanen K (1995) Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 15:959-964
42. Yasojima H, Shimomura A, Naoi Y, Kishi K, Baba Y, Shimazu K et al (2011) Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer. Eur J Cancer 12:1779-1788
43. Augenlicht LH, Wadler S, Corner G, Richards C, Ryan I, Multani AS et al (1997) Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57:1769-1775 (Pubitemid 27199672)
44. Iba T, Kigawa J, Kanantori Y, Itamochi H, Oishi T, Simada M et al (2006) Expression of the e c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci 95:418-423
45. Robertson JFR, Willsher PC, Cheung KL et al (1997) The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 33:1774-1779 (Pubitemid 28129202)
46. Schlotter CM, Vogt U, Bosse U, Mersch B, Wassmann K (2003) C-myc, not HER-2/neu, can predict recurrence and mortality of patients with node-negative breast cancer. Breast Cancer Res 5:R30-R36
47. Petrelli EF, Cabiddu M, Cazzaniga ME et al (2008) Targeted therapies for the treatment of breast cancer in the post-trastuzumab era. Oncologist 13:373-381 (Pubitemid 351679916)
48. Biliran H, Banerjee S, Thakur A et al (2007) C-Myc-induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-jB activity in pancreatic cancer cells. Clin Cancer Res 13:2811